Bausch Health Companies Inc. faces a challenging day on the TSX as its stock slips by over 2%.
Bausch Health Companies Inc. (BHC.TO) has seen its stock price decline by 2.16% in the last trading session, closing at CA$6.79. This drop comes despite recent positive developments regarding its product PrOKEDI, which has been listed in the RAMQ formulary in Quebec.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.56B
52W high
$11.97
52W low
$6.45
1W change
+0.87%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 1.0% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
+1.0% Upside
Current Price
C$6.94
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
48.8%
Annualized
90-Day Vol
42.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.81
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$6.54 | C$5.52 โ C$7.74 |
| 60 trading days | C$6.16 | C$4.85 โ C$7.82 |
| 90 trading days | C$5.81 | C$4.34 โ C$7.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Bausch Health's recent achievements may not be enough to offset current stock performance and market sentiment.
Bausch Health Companies Inc. stock down 2.16%
With a market cap of CA$2.56 billion and a profit margin of -11.47%, Bausch Health is struggling to gain investor confidence.
Bull case
The listing of PrOKEDI in the RAMQ formulary could improve access to treatment options, which might lead to increased revenue for Bausch Health in the long run.
Bear case
Despite this positive news, the stock's decline shows that investors are skeptical about the company's overall financial health and market position, especially considering its negative profit margin.
Stock Performance Overview
Bausch Health's stock closed at CA$6.79, reflecting a 2.16% decline in the last trading session. This drop raises questions about the company's market sentiment and future growth potential.
Recent Developments
Even with the stock's downturn, Bausch Health's announcement about the listing of PrOKEDI in the RAMQ formulary is a significant step forward. This injectable treatment for schizophrenia could potentially increase market access and revenue, yet investor confidence remains shaky.
Investor Sentiment
The negative profit margin of -11.47% and the stock's recent performance indicate that investors are wary of Bausch Health's financial stability. While the company is making strides in product access, the overall market reaction suggests a need for cautious optimism.
Advertisement
